AR120727A1 - PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME - Google Patents

PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME

Info

Publication number
AR120727A1
AR120727A1 ARP200103449A ARP200103449A AR120727A1 AR 120727 A1 AR120727 A1 AR 120727A1 AR P200103449 A ARP200103449 A AR P200103449A AR P200103449 A ARP200103449 A AR P200103449A AR 120727 A1 AR120727 A1 AR 120727A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
same
bpi
comprises bpi
Prior art date
Application number
ARP200103449A
Other languages
Spanish (es)
Inventor
Chengwu Yu
Xin Li
Chun Tang
Xiaoxia Zhang
Jirong Peng
Don Zhang
Yuelie Lu
Original Assignee
Beta Pharma Suzhou Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Suzhou Ltd filed Critical Beta Pharma Suzhou Ltd
Publication of AR120727A1 publication Critical patent/AR120727A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente describe una composición farmacéutica que comprende una sal farmacéuticamente aceptable de un compuesto de la fórmula (1), un diluyente, un disgregante y un lubricante. La composición farmacéutica puede disolverse extremadamente rápido y tiene una elevada biodisponibilidad de la droga y calidad estable. Además, la composición farmacéutica puede ser preparada mediante un método directo de rellenado en polvo, lo cual es adecuado para producción industrial.The present describes a pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of formula (1), a diluent, a disintegrant and a lubricant. The pharmaceutical composition can dissolve extremely fast and has high drug bioavailability and stable quality. Furthermore, the pharmaceutical composition can be prepared by a direct powder-filling method, which is suitable for industrial production.

ARP200103449A 2019-12-11 2020-12-11 PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME AR120727A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911264353.1A CN110898026A (en) 2019-12-11 2019-12-11 Pharmaceutical composition containing BPI-7711 and preparation method thereof

Publications (1)

Publication Number Publication Date
AR120727A1 true AR120727A1 (en) 2022-03-09

Family

ID=69824307

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103449A AR120727A1 (en) 2019-12-11 2020-12-11 PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME

Country Status (4)

Country Link
CN (1) CN110898026A (en)
AR (1) AR120727A1 (en)
TW (1) TW202122087A (en)
WO (1) WO2021115425A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898026A (en) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 Pharmaceutical composition containing BPI-7711 and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489B (en) * 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 Pyrimidine or pyridine compounds and their, preparation method and medical usage
MX2018015508A (en) * 2016-06-17 2019-04-11 Beta Pharma Inc Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy- 5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acryla mide and crystalline forms thereof.
CN110799191B (en) * 2017-06-16 2023-05-26 贝塔制药有限公司 Pharmaceutical formulations of N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide and salts thereof
CN110898026A (en) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 Pharmaceutical composition containing BPI-7711 and preparation method thereof

Also Published As

Publication number Publication date
TW202122087A (en) 2021-06-16
CN110898026A (en) 2020-03-24
WO2021115425A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
CR20220281A (en) Pyrazolyl derivatives useful as anti-cancer agents
MX2022015207A (en) Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX2022008066A (en) Substituted tricyclic compounds.
JOP20190070A1 (en) BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
MX2021012756A (en) Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof.
BR112018002499A2 (en) method of preparing a compound of formula (a) or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof, compound produced by the method and pharmaceutical composition
EA201201496A1 (en) A method of inhibiting HIV integrase, METHOD FOR IMPROVED PHARMACOKINETICS 6- (3-chloro-2-fluorobenzyl) -1 - [(2S) -1-Hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxo-1 4-DIHYDROCHINOLIN-3-CARBONIC ACID (OPTIONS), SET, PHARMACEUTICAL COMPOSITION (OPTIONS) AND ANTIRETROVIRAL AGENT (OPTIONS)
MX2022001784A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents.
SA520411524B1 (en) Bisamide sarcomere activating compounds and uses thereof
MX2020009530A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors.
DOP2024000039A (en) QUINOLINE DERIVATIVES AS ALFA4BETA7 INTEGRIN INHIBITORS
EA201990455A1 (en) CONDENSED TRICYCLIC DERIVATIVE OF γ-AMINO ACIDS, METHOD FOR ITS PRODUCTION AND ITS MEDICAL APPLICATION
MX2017012295A (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors.
MX2022004451A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases.
MX2018014374A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same.
MX2024000299A (en) Anti-viral compounds.
WO2018125961A8 (en) Poly-adp ribose polymerase (parp) inhibitors
MX2022005615A (en) Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof.
MX2022004450A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases.
MX2021003662A (en) Aminonordecane derivative, and preparation method therefor and application thereof.
TN2016000489A1 (en) Carboxamide derivatives.
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
CO2022008616A2 (en) Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor
AR086987A1 (en) 1-PIPERAZINO-3-PHENYL-INDANOS DEUTERATED FOR THE TREATMENT OF SCHIZOPHRENIA

Legal Events

Date Code Title Description
FB Suspension of granting procedure